XNCRXencor, Inc.
Is the business good?
Margins compressing. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Operating margin has narrowed over the past few years, profitability per dollar of sales is eroding.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is XNCR?
Xencor, Inc. earns −30% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
Return on invested capital · cost of capital 9.0% · 39 points below what the capital costs: growth destroys value
- Operating margin
- −206%
Operating margin · Biotechnology median −77% · 12 months to Q2 2026
- Share count, year on year
- +2.1%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 244%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | −63% |
| FY2021 | 16% |
| FY2022 | −50% |
| FY2023 | −76% |
| FY2024 | −161% |
| FY2025 | −141% |
Details›
- Operating margin12 months to Q2 2026
- −206%
- Net margin12 months to Q2 2026
- −156%
- Free cash flow margin
- −198%
- R&D as % of revenue
- 244%
- Revenue, trailing twelve months
- $105M
- Free cash flow, trailing twelve months
- −$208M
- Net income, trailing twelve months
- −$163M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- −30%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.